IE38521L - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
IE38521L
IE38521L IE732082A IE208273A IE38521L IE 38521 L IE38521 L IE 38521L IE 732082 A IE732082 A IE 732082A IE 208273 A IE208273 A IE 208273A IE 38521 L IE38521 L IE 38521L
Authority
IE
Ireland
Prior art keywords
acid
aluminium
glycyrrhetininc
salts
antacid
Prior art date
Application number
IE732082A
Other versions
IE38521B1 (en
Original Assignee
Biorex Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Laboratories Ltd filed Critical Biorex Laboratories Ltd
Publication of IE38521L publication Critical patent/IE38521L/en
Publication of IE38521B1 publication Critical patent/IE38521B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1401360 Pharmaceutical compositions BIOREX LABORATORIES LTD 29 Nov 1973 [18 Dec 1972] 58355/72 Heading A5B Pharmaceutical compositions for use in the treatment of gastritis in dosage unit form comprise 1-100 mg of at least one non-ulcerogenic, anti-inflammatory active derivative of glycyrrhetinic acid (selected from the esters, hemiesters and hemiester salts thereof e.g. the disodium salt of glycyrrhetininc acid hemisuccinate, the salts of glycyrrhetinic acid with non-toxic organic bases; the salts of glycyrrhetinic acid and its hemiesters with bismuth, zinc or a metal of Group IIA, IIIA or VIII of the Periodic Table; and the amides of glycyrrhetininc acid and of acylated glycyrrhetininc acid), in admixture with 1-70% by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound (such as aluminium hydroxide, aluminium magnesium silicate, aluminium phosphate, or dihydroxyaluminium aminoacetate). The antacid aluminium compound may be partially replaced by other known antacid compounds e.g. calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate or sodium bicarbonate. The composition may be administered orally in the form of a tablet. [GB1401360A]
IE2082/73A 1972-12-18 1973-11-16 Pharmaceutical composition IE38521B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5835572A GB1401360A (en) 1972-12-18 1972-12-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
IE38521L true IE38521L (en) 1974-06-18
IE38521B1 IE38521B1 (en) 1978-03-29

Family

ID=10481403

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2082/73A IE38521B1 (en) 1972-12-18 1973-11-16 Pharmaceutical composition

Country Status (10)

Country Link
AU (1) AU476390B2 (en)
BE (1) BE802701A (en)
CA (1) CA1018457A (en)
DE (1) DE2360889A1 (en)
FR (1) FR2210400B1 (en)
GB (1) GB1401360A (en)
IE (1) IE38521B1 (en)
IL (1) IL42314A (en)
NL (1) NL7317237A (en)
ZA (1) ZA732439B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8307096A1 (en) * 1981-06-01 1983-07-01 Orion Yhtymae Oy Tablets which do not damage the oesophagus.
GB2122893B (en) * 1982-06-30 1985-06-26 Biorex Laboratories Ltd Glycyrrhetinic acid compositions
AU553789B2 (en) * 1982-06-30 1986-07-24 Biorex Laboratories Ltd. Glycyrrhetinic acid derivatives in cream compositions
US4861591A (en) * 1987-11-18 1989-08-29 American Home Products Corporation Formulations for hygroscopic pharmaceuticals

Also Published As

Publication number Publication date
FR2210400A1 (en) 1974-07-12
AU476390B2 (en) 1976-09-16
IL42314A0 (en) 1973-07-30
ZA732439B (en) 1974-03-27
BE802701A (en) 1974-01-23
AU6312773A (en) 1975-06-05
NL7317237A (en) 1974-06-20
FR2210400B1 (en) 1977-07-15
CA1018457A (en) 1977-10-04
IL42314A (en) 1976-09-30
GB1401360A (en) 1975-07-16
IE38521B1 (en) 1978-03-29
DE2360889A1 (en) 1974-06-20

Similar Documents

Publication Publication Date Title
IE38520B1 (en) Pharmaceutical composition
ES475338A1 (en) o-Substituted (+)-cyanidan-3-ol derivatives, method for their preparation, as well as pharmaceutical compositions containing these compounds and their preparation.
IE38521L (en) Pharmaceutical composition
IE33477L (en) Naphthacene derivatives
GB1246141A (en) Improvements in or relating to -hydroxylproline derivatives
JPS5673089A (en) Therapeutic creatinolloophosphate derivative* its manufacture* related pharmaceutic composition and therapy
GB906331A (en) Appetite-reducing compositions comprising phenylamino propane derivatives
ES474733A1 (en) Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them.
ES8203882A1 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine.
US3787581A (en) Pharmaceutical compositions and methods of treatment
US3501577A (en) Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate
SU1251904A1 (en) Composition for mineralization of teeth
GB1246902A (en) Improvements in therapeutic agents
ES8305759A1 (en) Pyrrolidinone derivatives, their preparation and pharmaceutical compositions containing them.
GB1243159A (en) Sulphuric acid half-esters of tragacanth and preparation thereof
GB1265627A (en)
US3968145A (en) Methyl 2(1 chloronaphth-2-yloxy)propionate
GB1350929A (en) Pharmaceutical compositions
GB1276589A (en) 0-alkyl-6-azauracil compounds and compositions containing the same
Yendt Drugs used in the management of renal calculi
GB1464082A (en) Pharmaceutical 'ompositions containing benzylamines
GB1217822A (en) Pharmaceutical compositions
GB1342540A (en) Sulphonic acid esters their preparation and their medicinal use
GB828729A (en) Therapeutic compositions containing novobiocin
GB1280244A (en) Serum triglyceride-lowering compositions